Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Rhea-AI Summary

Clearmind (NASDAQ: CMND) announced that its proprietary compound MEAI (5-MeO-AI) was named in newly introduced bipartisan U.S. legislation, the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091). The bill would direct the VA to create investigational research and extended access programs covering MEAI and other emerging therapies.

If passed, H.R. 7091 aims to support VA-backed clinical trials and extended access protocols for conditions including Alcohol Use Disorder and PTSD, expanding veteran access to innovative treatments.

Positive

• MEAI explicitly named in introduced federal legislation
• H.R. 7091 would direct VA to fund investigational research programs
• Bill covers multiple therapies including MEAI, psilocybin, MDMA, ketamine

Negative

• Legislation is introduced but not yet passed or enacted
• No financial, trial-schedule, or regulatory-approval details provided

News Market Reaction

-5.83%

7 alerts

-5.83% News Effect

+15.3% Peak Tracked

-26.8% Trough Tracked

-$207K Valuation Impact

$3M Market Cap

0.9x Rel. Volume

On the day this news was published, CMND declined 5.83%, reflecting a notable negative market reaction. Argus tracked a peak move of +15.3% during that session. Argus tracked a trough of -26.8% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $207K from the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Bill number: H.R. 7091

1 metrics

Bill number H.R. 7091 Expanding Veterans’ Access to Emerging Treatments Act of 2026

Market Reality Check

Price: $1.45 Vol: Volume 45,298 is below th...

low vol

$1.45 Last Close

Volume Volume 45,298 is below the 20-day average of 124,296 (relative volume 0.36), suggesting limited pre-news participation. low

Technical At $2.23, CMND trades well below its 200-day MA of $29.43 and 96.28% below the $60.00 52-week high, despite being 27.94% above the $1.743 52-week low.

Peers on Argus

CMND is up 2.76% while close biotech peers show mixed moves: several are down (e...

1 Down

CMND is up 2.76% while close biotech peers show mixed moves: several are down (e.g., TTNP -3.96%, SILO -5.25%), with one notable gainer (PLRZ +17.12%). Momentum scanner shows only one peer (ADTX -7.01%) in action, reinforcing a stock-specific reaction.

Historical Context

5 past events · Latest: Jan 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Annual report filing	Neutral	+5.6%	Filed Form 20-F annual report for fiscal year ended October 31, 2025.
Jan 14	Clinical trial update	Positive	+0.4%	All patients in second cohort of Phase I/IIa CMND-100 trial completed treatment.
Dec 31	Listing compliance	Positive	-2.7%	Regained compliance with Nasdaq minimum bid price requirement under Listing Rule 5550(a)(2).
Dec 24	Year-in-review update	Positive	-5.8%	Highlighted 2025 clinical advances for CMND-100 and expanded global trial footprint.
Dec 16	Clinical enrollment	Positive	-3.7%	Announced completion of second cohort enrollment in Phase I/IIa CMND-100 trial.

Pattern Detected

Recent history shows several positive operational updates followed by negative price reactions, indicating a tendency for the stock to sell off or underreact to seemingly favorable news.

Recent Company History

Over the past few months, Clearmind has reported multiple clinical and corporate milestones. These include completion of second-cohort enrollment and treatment in its FDA-approved Phase I/IIa trial for CMND-100 in Alcohol Use Disorder, a year-end review highlighting first-in-human dosing and multinational site activations, and regaining Nasdaq minimum bid compliance. Administrative updates such as the Form 20-F filing also appeared. Price reactions have been mixed, with some clinical and compliance updates followed by declines, suggesting investor caution around early-stage progress and the company’s broader risk profile.

Market Pulse Summary

The stock moved -5.8% in the session following this news. A negative reaction despite this legislati...

Analysis

The stock moved -5.8% in the session following this news. A negative reaction despite this legislative milestone would fit a pattern where CMND has sometimes declined on seemingly favorable news, including prior clinical and compliance updates. With the stock at $2.23, far below the $60.00 52-week high and 200-day MA of $29.43, sentiment has been fragile. Investors may be weighing long regulatory and clinical timelines and the company’s broader risk disclosures against the long-term potential implied by MEAI’s inclusion in federal legislation.

Key Terms

neuroplastogen, psilocybin, mdma, 5-meo-dmt, +4 more

8 terms

neuroplastogen medical

"Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S."

A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.

psilocybin medical

"Covered therapies explicitly include psilocybin, MDMA, MEAI (5-MeO-AI), 5-MeO-DMT,"

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

mdma medical

"Covered therapies explicitly include psilocybin, MDMA, MEAI (5-MeO-AI), 5-MeO-DMT,"

MDMA (3,4-methylenedioxymethamphetamine) is a synthetic psychoactive compound best known for producing strong mood and empathy effects; it appears both as a recreational drug and as an experimental medicine used alongside psychotherapy. Investors watch MDMA because positive clinical results or regulatory changes can create a new prescription market—like discovering a potent new ingredient for treatments—while legal controls, safety data, and public perception can sharply limit commercial and financial upside.

5-meo-dmt medical

"psilocybin, MDMA, MEAI (5-MeO-AI), 5-MeO-DMT, ibogaine, ketamine, and others"

5-MeO-DMT is a naturally occurring psychoactive chemical that produces intense, short-lived changes in perception and mood; think of it as a powerful, brief brain 'reset' rather than a typical recreational drug. It matters to investors because research, clinical testing, legal status, and safety data determine whether companies can develop it into regulated therapies or commercial products, shaping potential market size, regulatory risk, and public acceptance.

ibogaine medical

"psilocybin, MDMA, MEAI (5-MeO-AI), 5-MeO-DMT, ibogaine, ketamine, and others"

A naturally derived psychoactive compound used experimentally to treat substance use disorders and certain mental health conditions; it acts on the brain to reduce cravings and withdrawal symptoms. Investors care because a successful, approved therapy could open a new treatment market, while safety concerns, mixed clinical evidence, and strict regulatory oversight create high development risk—think of it as an experimental key that may unlock value but must pass several safety locks first.

ketamine medical

"psilocybin, MDMA, MEAI (5-MeO-AI), 5-MeO-DMT, ibogaine, ketamine, and others"

A fast-acting anesthetic drug that is also used at lower doses to treat severe depression and certain pain conditions; it works differently from traditional antidepressants and can produce rapid symptom relief, often described as a short-term “reset” of brain activity. Investors watch ketamine because clinical trial results, regulatory approvals, safety concerns, legal status, production scale, and potential off-label use drive demand, pricing, and the business prospects of companies involved in its manufacture and delivery.

alcohol use disorder medical

"covered conditions, including Alcohol Use Disorder, by developing VA-supported"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

post-traumatic stress disorder medical

"veterans suffering from alcoholism, post-traumatic stress disorder and other conditions"

A mental health condition that can develop after a person experiences or witnesses a traumatic event, causing persistent symptoms such as intrusive memories, heightened stress reactions, avoidance of reminders, and trouble sleeping or concentrating. For investors it matters because it can reduce employee productivity, increase healthcare and disability costs, alter consumer behavior, and create demand for treatment and support services—think of a business whose systems keep freezing after a shock, requiring ongoing fixes and higher operating costs.

AI-generated analysis. Not financial advice.

This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation

Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems,  today welcomes the inclusion of its proprietary compound, MEAI (5-methoxy-2-aminoindane,or5-MeO-AI ), in newly introduced bipartisan legislation in the U.S. Congress.

The Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091) directs the Department of Veterans Affairs (VA) to establish an investigational research and extended access treatment program for innovative and emerging therapies that address unmet medical needs in veterans.

Covered therapies explicitly include psilocybin, MDMA, MEAI (5-MeO-AI), 5-MeO-DMT, ibogaine, ketamine, and others as designated by the Secretary of Veterans Affairs. This marks the first time MEAI, Clearmind’s proprietary, next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation. If passed, H.R. 7091 would transform clinical treatment across a variety of covered conditions, including Alcohol Use Disorder, by developing VA-supported clinical trials and extended access protocols using these emerging treatments.

“We so greatly appreciate Congress introducing H.R. 7091, which offers a transformational opportunity for veterans suffering from alcoholism, post-traumatic stress disorder and other conditions to access emerging, promising therapies. We also appreciate the recognition of MEAI, a non-hallucinogenic neuroplastogen with the transformative potential to improve the health of veterans,” said Clearmind Medicine CEO Dr. Adi Zuloff-Shani, PhD. “We believe, this bipartisan milestone in Washington, D.C., underscores growing support for innovative, evidence-based approaches to conditions like post-traumatic stress disorder, which remains a significant challenge for many veterans.”

"This bill, with the inclusion of MEAI and other innovative therapies, forges a new vocabulary for evidence-based psychedelic healing,” said Melissa Lavasani, Founder and CEO of the Washington, D.C, non-profit Psychedelic Medicine Coalition.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how H.R. 7091, if passed, would transform clinical treatment across a variety of covered conditions, including Alcohol Use Disorder, by developing VA-supported clinical trials and extended access protocols using these emerging treatments, how MEAI has the transformative potential to improve the health of veterans and the growing support for innovative, evidence-based approaches to conditions like post-traumatic stress disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What did Clearmind (CMND) announce about MEAI on February 3, 2026?

Clearmind announced that MEAI was named in H.R. 7091, bipartisan legislation to expand veteran access to emerging therapies. According to the company, the bill would direct the VA to establish investigational research and extended access programs covering MEAI and similar treatments.

What does H.R. 7091 propose for MEAI and veteran care under CMND (CMND)?

H.R. 7091 would direct the Department of Veterans Affairs to establish investigational research and extended access programs for covered therapies. According to the company, MEAI is listed among therapies that could be included in VA-supported trials and extended access protocols.

Does the inclusion of MEAI in H.R. 7091 mean immediate VA adoption for Clearmind (CMND)?

No, inclusion does not guarantee immediate adoption; the bill must pass and be implemented first. According to the company, H.R. 7091 would enable VA-supported trials and access programs only if enacted and acted upon by the VA.

Which conditions could MEAI address if H.R. 7091 enables VA programs for CMND (CMND)?

The bill targets unmet veteran needs such as Alcohol Use Disorder and PTSD among covered conditions. According to the company, H.R. 7091 would support clinical trials and extended access protocols using MEAI and other listed therapies.

What is the potential significance for investors in Clearmind (CMND) from MEAI’s naming in H.R. 7091?

The naming increases visibility for MEAI within federal policy discussions but is not a regulatory approval. According to the company, the milestone reflects bipartisan recognition while actual impact depends on bill passage and VA program implementation.